-transparent.png){kind=logo}
The use of retinoic acid is a new approach in the treatment of acute promyelocytic leukemia. We outline the therapy in a 61-year-old patient with acute promyelocytic leukemia who had not responded to standard chemotherapy but in whom the administration of 13-cis-retinoic acid resulted in complete remission for 24 months. In relapse the patient was treated with all-trans-retinoic acid in combination with two cycles of daunorubicin and cytosine arabinoside and achieved another complete remission.
Related Publications
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
March 1998,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
December 1992,
Harefuah,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
August 2011,
Zhonghua yi xue za zhi,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
January 1995,
Annals of the Academy of Medicine, Singapore,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
December 1990,
Lancet (London, England),
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
September 2000,
American journal of hematology,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
January 1999,
Oncology reports,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
February 1993,
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
July 1997,
Internal medicine (Tokyo, Japan),
T Haferlach, and
H Löffler, and
B Glass, and
W Gassmann
March 1988,
Zhonghua yi xue za zhi,
